TapewireFind a company

person · Reporting owner

Collins Cynthia

Disclosed activity across 6 companies

Tapewire entity
36312
SEC CIK
0001405692

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CODEXIS, INC.CDXS · Entity 6428DirectorJune 17, 2026June 18, 2026
DermTech, Inc.DMTK · Entity 89998DirectorJune 01, 2023June 05, 2023
Editas Medicine, Inc.EDIT · Entity 5502CEOFebruary 09, 2021February 10, 2021
MAXCYTE, INC.MXCT · Entity 6608DirectorJune 17, 2026June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CODEXIS, INC.

Report date June 17, 2026 · Filed June 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2036-06-17Direct66,350 Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-17 · Grant · Acquired 66,350 · Balance 66,350

F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

DermTech, Inc.

Report date June 01, 2023 · Filed June 05, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect104,835 Reported balance After 2023-06-01 transaction · row 1
1 source row

Row 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 104,835

F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.

Editas Medicine, Inc.

Report date February 09, 2021 · Filed February 10, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect43,760 Reported balance After 2021-02-09 transaction · row 1
1 source row

Row 1 · 2021-02-09 · Sale · Disposed 1,262 · Balance 43,760

F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2021. The sale does not represent a discretionary trade by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $66.47 to $66.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filing footnotes · ownership attribution and instrument terms

F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2021. The sale does not represent a discretionary trade by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $66.47 to $66.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

MAXCYTE, INC.

Report date June 17, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect111,310 Reported balance After 2026-06-17 transaction · row 1
1 source row

Row 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 111,310

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16Direct49,579 Reported balance After 2026-06-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579

F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Certara, Inc.

Report date May 14, 2026 · Filed May 15, 2026

Section 16 reporting ended · disclosed 2026-05-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect51,846 Reported balance After 2026-05-14 transaction · row 1
1 source row

Row 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 51,846

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Poseida Therapeutics, Inc.

Report date January 08, 2025 · Filed January 08, 2025

Section 16 reporting ended · disclosed 2025-01-08. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2025-01-08 transaction · row 1
1 source row

Row 1 · 2025-01-08 · Other · Disposed 58,950 · Balance 0

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2031-07-22Direct0 Reported balance After 2025-01-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2025-01-08 · Disposition to issuer · Disposed 87,440 · Balance 0

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2032-06-15Direct0 Reported balance After 2025-01-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2025-01-08 · Disposition to issuer · Disposed 28,500 · Balance 0

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2033-06-14Direct0 Reported balance After 2025-01-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-01-08 · Disposition to issuer · Disposed 27,350 · Balance 0

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.81 · Expires 2034-06-16Direct0 Reported balance After 2025-01-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-01-08 · Disposition to issuer · Disposed 27,350 · Balance 0

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 17, 2026 Filed Jun 18, 2026 20:57 UTC CODEXIS, INC. CDXS · Entity 6428 GrantStock Option (Right to Buy) · Derivative 66,350 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001610717-26-000272 · form4.xml · derivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,350

Underlying: Common Stock · 66,350 shares

Expires 2036-06-17

F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:25 UTC MAXCYTE, INC. MXCT · Entity 6608 GrantStock Option (right to buy) · Derivative 49,579 $0.00 Strike: $1.13 $0.00
Disclosure

SEC source: 0000905148-26-003052 · form4.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,579

Underlying: Common Stock · 49,579 shares

Expires 2036-06-16

F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:25 UTC MAXCYTE, INC. MXCT · Entity 6608 GrantCommon Stock 30,421 $0.00 $0.00
Disclosure

SEC source: 0000905148-26-003052 · form4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,310

F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Read SEC document
May 14, 2026 Filed May 15, 2026 20:31 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 15,757 $0.00 $0.00
Disclosure

SEC source: 0001405692-26-000002 · form4-05152026_080516.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,757 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Read SEC document
May 14, 2026 Filed May 15, 2026 20:31 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 15,757 $0.00 $0.00
Disclosure

SEC source: 0001405692-26-000002 · form4-05152026_080516.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 22:38 UTC MAXCYTE, INC. MXCT · Entity 6608 GrantStock Option (right to buy) · Derivative 50,790 $0.00 Strike: $2.11 $0.00
Disclosure

SEC source: 0000905148-25-002231 · form4.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,790

Underlying: Common Stock · 50,790 shares

Expires 2035-06-17

F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 22:38 UTC MAXCYTE, INC. MXCT · Entity 6608 GrantCommon Stock 29,210 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-002231 · form4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,889

F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 23:28 UTC CODEXIS, INC. CDXS · Entity 6428 GrantCommon Stock 40,983 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-002128 · form4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,157

F1 · shares: The restricted stock units vest as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

Read SEC document
May 21, 2025 Filed May 22, 2025 21:01 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 15,757 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-014189 · form4-05222025_090546.xml · derivative · entry 3

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,757

Underlying: Common Stock · 15,757 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.exercise_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.expiration_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

Read SEC document
May 21, 2025 Filed May 22, 2025 21:01 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 11,928 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-014189 · form4-05222025_090546.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,928 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

Read SEC document
May 21, 2025 Filed May 22, 2025 21:01 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 11,928 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-014189 · form4-05222025_090546.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.

Read SEC document
March 28, 2025 Filed Apr 1, 2025 16:39 UTC CODEXIS, INC. CDXS · Entity 6428 GrantCommon Stock 71,174 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-001032 · form4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,174

F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting dates.

Read SEC document
January 08, 2025 Filed Jan 8, 2025 14:14 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 Disposition to issuerStock Option (Right to Buy) · Derivative 27,350 $0.00 Strike: $2.81 $0.00
Disclosure

SEC source: 0001415889-25-001086 · form4-01082025_070116.xml · derivative · entry 5

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,350 shares

Expires 2034-06-16

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Read SEC document
January 08, 2025 Filed Jan 8, 2025 14:14 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 Disposition to issuerStock Option (Right to Buy) · Derivative 27,350 $0.00 Strike: $2.47 $0.00
Disclosure

SEC source: 0001415889-25-001086 · form4-01082025_070116.xml · derivative · entry 4

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,350 shares

Expires 2033-06-14

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Read SEC document
January 08, 2025 Filed Jan 8, 2025 14:14 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 Disposition to issuerStock Option (Right to Buy) · Derivative 28,500 $0.00 Strike: $2.01 $0.00
Disclosure

SEC source: 0001415889-25-001086 · form4-01082025_070116.xml · derivative · entry 3

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,500 shares

Expires 2032-06-15

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Read SEC document
January 08, 2025 Filed Jan 8, 2025 14:14 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 Disposition to issuerStock Option (Right to Buy) · Derivative 87,440 $0.00 Strike: $8.63 $0.00
Disclosure

SEC source: 0001415889-25-001086 · form4-01082025_070116.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 87,440 shares

Expires 2031-07-22

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Read SEC document
January 08, 2025 Filed Jan 8, 2025 14:14 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 OtherCommon Stock 58,950 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-001086 · form4-01082025_070116.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]

F2 · shares: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]

F2 · price: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 21:36 UTC MAXCYTE, INC. MXCT · Entity 6608 GrantStock Option (right to buy) · Derivative 97,698 $0.00 Strike: $3.87 $0.00
Disclosure

SEC source: 0000905148-24-002726 · form4.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,698

Underlying: Common Stock · 97,698 shares

Expires 2034-10-13

F2 · derivative.exercise_date: One-third of the shares underlying this option shall vest on October 14, 2025, and the remainder shall vest in twenty-four (24) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
October 14, 2024 Filed Oct 16, 2024 21:36 UTC MAXCYTE, INC. MXCT · Entity 6608 GrantCommon Stock 51,679 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-002726 · form4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,679

F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One hundred percent (100%) of the RSUs shall vest on October 14, 2025, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Read SEC document
June 17, 2024 Filed Jun 18, 2024 16:14 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 GrantStock Option (Right to buy) · Derivative 27,350 $0.00 Strike: $2.81 $0.00
Disclosure

SEC source: 0000950170-24-074865 · ownership.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,350

Underlying: Common Stock · 27,350 shares

Expires 2034-06-16

F2 · derivative.exercise_date: The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.

Read SEC document
June 17, 2024 Filed Jun 18, 2024 16:14 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 GrantCommon Stock 19,650 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-074865 · ownership.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,950

F1 · kind: Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:29 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 11,928 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-014263 · form4-05232024_080526.xml · derivative · entry 3

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,928

Underlying: Common Stock · 11,928 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.exercise_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

F2 · derivative.expiration_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:29 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 8,663 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-014263 · form4-05232024_080526.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,663 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

Read SEC document
May 21, 2024 Filed May 23, 2024 20:29 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 8,663 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-014263 · form4-05232024_080526.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting.

Read SEC document
June 15, 2023 Filed Jun 16, 2023 16:10 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 GrantStock Option (Right to buy) · Derivative 27,350 $0.00 Strike: $2.47 $0.00
Disclosure

SEC source: 0000950170-23-028609 · ownership.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,350

Underlying: Common Stock · 27,350 shares

Expires 2033-06-14

F2 · derivative.exercise_date: The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.

Read SEC document
June 15, 2023 Filed Jun 16, 2023 16:10 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 GrantCommon Stock 19,650 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-028609 · ownership.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,300

F1 · kind: Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.

Read SEC document
June 01, 2023 Filed Jun 5, 2023 22:45 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 35,714 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-034623 · doc4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,835

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.

Read SEC document
May 23, 2023 Filed May 25, 2023 12:41 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 8,663 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-008748 · form4-05252023_120541.xml · derivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,663

Underlying: Common Stock · 8,663 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted on May 23, 2023, under the Certara Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted on May 23, 2023, under the Certara Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted on May 23, 2023, under the Certara Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual shareholder meeting.

Read SEC document
May 17, 2023 Filed May 19, 2023 12:34 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionRestricted Stock Units · Derivative 9,067 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-008304 · form4-05192023_120506.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,067 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant.

Read SEC document
May 17, 2023 Filed May 19, 2023 12:34 UTC Certara, Inc. CERT · Entity 787 Exercise / conversionCommon Stock 9,067 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-008304 · form4-05192023_120506.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents restricted stock units ("RSUs") granted under the Certara, Inc. 2020 Incentive Plan that entitles the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs vested and were converted into common shares on the one-year anniversary of the date of grant.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 10:44 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 GrantStock Option (Right to Buy) · Derivative 28,500 $0.00 Strike: $2.01 $0.00
Disclosure

SEC source: 0001209191-22-037711 · doc4.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2032-06-15

F2 · derivative.exercise_date: The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 10:44 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 GrantCommon Stock 19,650 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-037711 · doc4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,650

F1 · kind: Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.

Read SEC document
May 26, 2022 Filed Jun 1, 2022 01:01 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 26,480 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-033016 · doc4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,121

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2023.

Read SEC document
May 17, 2022 Filed May 18, 2022 20:37 UTC Certara, Inc. CERT · Entity 787 GrantRestricted Stock Units · Derivative 9,067 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-005245 · form4-05182022_010540.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,067

Underlying: Common Stock · 9,067 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock.

F3 · shares: Represents 9,067 RSUs granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual shareholder meeting. The reporting person has reported prior awards of RSUs in Table 1 of Form 4.

F4 · derivative.exercise_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual shareholder meeting.

F4 · derivative.expiration_date: The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual shareholder meeting.

Read SEC document
August 01, 2021 Filed Aug 3, 2021 20:46 UTC Certara, Inc. CERT · Entity 787 GrantCommon Stock 6,431 $0.00 $0.00
Disclosure

SEC source: 0001415889-21-003770 · form4-08032021_010824.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,431

F1 · kind: Represents 6,431 restricted stock units ("RSU") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting.

Read SEC document
July 23, 2021 Filed Jul 26, 2021 20:29 UTC Poseida Therapeutics, Inc. PSTX · Entity 84243 GrantStock Option (Right to Buy) · Derivative 87,440 $0.00 Strike: $8.63 $0.00
Disclosure

SEC source: 0001209191-21-048255 · doc4.xml · derivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,440

Underlying: Common Stock · 87,440 shares

Expires 2031-07-23

F1 · derivative.exercise_date: The stock option will vest and become exercisable in 36 equal monthly installments following the grant date set forth in column 3 above.

Read SEC document
May 26, 2021 Filed May 29, 2021 00:15 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 4,661 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-036708 · doc4.xml · nonDerivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,641

F2 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest, and the shares underlying the restricted stock units shall be released to the reporting person, on January 1, 2023, subject to the reporting person's continued service.

Read SEC document
May 26, 2021 Filed May 29, 2021 00:15 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 4,497 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-036708 · doc4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,980

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on January 3, 2023.

Read SEC document
February 09, 2021 Filed Feb 10, 2021 21:26 UTC Editas Medicine, Inc. EDIT · Entity 5502 SaleCommon Stock 1,262 $66.65 $84,112.30
Disclosure

SEC source: 0001179110-21-001512 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,760

F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2021. The sale does not represent a discretionary trade by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $66.47 to $66.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 20, 2020 Filed Aug 21, 2020 20:12 UTC Editas Medicine, Inc. EDIT · Entity 5502 SaleCommon Stock 1,976 $36.66 $72,440.16
Disclosure

SEC source: 0001179110-20-009219 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,022

F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 19, 2020. The sale does not represent a discretionary trade by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $36.44 to $36.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 17, 2020 Filed Jun 19, 2020 20:13 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 8,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-037910 · doc4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,483

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. All of the restricted stock units shall vest in a single installment on June 17, 2021, subject to the reporting person's continued service through the earlier to occur of (i) June 17, 2021 or (ii) the date of the issuer's 2021 Annual Meeting of Stockholders.

Read SEC document
February 06, 2020 Filed Feb 10, 2020 21:32 UTC Editas Medicine, Inc. EDIT · Entity 5502 GrantStock Option (right to buy) · Derivative 93,750 $0.00 Strike: $28.05 $0.00
Disclosure

SEC source: 0001179110-20-001362 · edgar.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,750

Underlying: Common Stock · 93,750 shares

Expires 2030-02-05

F2 · derivative.exercise_date: This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.

Read SEC document
February 06, 2020 Filed Feb 10, 2020 21:32 UTC Editas Medicine, Inc. EDIT · Entity 5502 GrantCommon Stock 15,625 $0.00 $0.00
Disclosure

SEC source: 0001179110-20-001362 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,998

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 21:07 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 6,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-005975 · doc4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,483

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's Amended and Restated 2010 Stock Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, all of the restricted stock units shall vest in a single installment on the date of the 2020 annual meeting of the stockholders of the issuer.

Read SEC document
December 31, 2019 Filed Jan 3, 2020 17:04 UTC DermTech, Inc. DMTK · Entity 89998 Exercise / conversionRestricted Stock Units · Derivative 8,755 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-000596 · doc4.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,755 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019.

F2 · derivative.expiration_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019.

Read SEC document
December 31, 2019 Filed Jan 3, 2020 17:04 UTC DermTech, Inc. DMTK · Entity 89998 Exercise / conversionCommon Stock 8,755 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-000596 · doc4.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
September 11, 2019 Filed Sep 13, 2019 20:06 UTC Editas Medicine, Inc. EDIT · Entity 5502 GrantStock Option (right to buy) · Derivative 250,000 $0.00 Strike: $26.57 $0.00
Disclosure

SEC source: 0001179110-19-010316 · edgar.xml · derivative · entry 3

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2024-08-19

F3 · derivative.exercise_date: This option was granted on September 11, 2019 and is scheduled to vest as to one-third of the shares underlying the option when the closing price of the Issuer's common stock, as reported on the Nasdaq Global Select Market, has for 15 consecutive trading days equaled or exceeded $50.00, $75.00 and $100.00 per share, respectively.

Read SEC document
September 11, 2019 Filed Sep 13, 2019 20:06 UTC Editas Medicine, Inc. EDIT · Entity 5502 GrantStock Option (right to buy) · Derivative 500,000 $0.00 Strike: $26.57 $0.00
Disclosure

SEC source: 0001179110-19-010316 · edgar.xml · derivative · entry 2

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2029-09-10

F2 · derivative.exercise_date: This option was granted on September 11, 2019 and is scheduled to vest over four years, with 25% of the shares to vest on August 19, 2020 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 19, 2023.

Read SEC document
September 11, 2019 Filed Sep 13, 2019 20:06 UTC Editas Medicine, Inc. EDIT · Entity 5502 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001179110-19-010316 · edgar.xml · nonDerivative · entry 1

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,373

F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on August 19, 2019 through August 19, 2022.

F1 · shares: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on August 19, 2019 through August 19, 2022.

Read SEC document
August 19, 2019 Filed Aug 21, 2019 20:03 UTC Editas Medicine, Inc. EDIT · Entity 5502 SaleCommon Stock 5,193 $25.83 $134,135.19
Disclosure

SEC source: 0001179110-19-009744 · edgar.xml · nonDerivative · entry 2

Collins Cynthia · CIK 0001405692 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,373

F2 · kind: The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction letter entered into between the Reporting Person and the issuer in connection with the Reporting Person receiving restricted stock unit awards from the issuer, and represent the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 19, 2019. The sales do not represent a discretionary trade by the Reporting Person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.